Genome-wide CRISPR/Cas9 library screening identified OGDH as a regulator of disease progress and HMAs-resistance in MDS by reprogramming glutamine metabolism

ABSTRACT: Resistance of hypomethylating agents (HMAs) remains a challenge in myelodysplastic neoplasms (MDS), leading to a poor prognosis. Altered metabolism is also reported to be closely associated with drug resistance in hematological malignancies. Here, we conducted a genome-wide CRISPR/Cas9 library screening to identify candidate genes involved in drug sensitivity.

ORGANISM(S): Homo sapiens

PROVIDER: GSE273914 | GEO | 2024/08/05

REPOSITORIES: GEO